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Prologue
Popularity of simulation techniques keeps growing in the field of health services
research. Discrete event simulation is being used more and more for economic eval-
uation, although it was initially applied for planning of healthcare resources. In the
context of population-based screening programs, discrete event simulation models
offer a tool to predict future needs of services according to the population structure
and, thus, represent a useful tool for health care planners and decision-makers. The
case of colorectal cancer screening is currently in the frontline, as the Catalan Direc-
tor Plan of Oncology has carried out the extension of the Program to all the Catalan
territory during 2015, which will imply that in 2016 the Program will be active and
generating needs of colonoscopies in all Catalonia. Colorectal cancer presents a
particularity in front of other cancers. The natural history of colorectal cancer
presents premalignant stages in the form of polyps or adenomas, which can be de-
tected and removed through colonoscopy to prevent them to reach a cancer stage.
Even if all adenomas are removed, future surveillance under colonoscopy is required
to remove new adenomas or adenomas not found in the previous colonoscopy. The
intensity of surveillance and the complexity of the surveillance colonoscopies will
depend on its number and size. In summary, the impact of extending the Colorectal
Cancer Screening Program to the whole territory will have a great impact in the
demand of colonoscopies, not only those colonoscopies needed to confirm the diag-
nostic after a positive screening test, but also the colonoscopies needed to make a
long-term follow-up of those men and women with premalignant findings. Meeting
this increased demand represents a challenge to the National Health Service and,
thus, careful planning of resources and of training of specialized professionals is
needed, taking into account population ageing and specificities of the health areas.
The present simulation model and dissertation is a step forward the introduction
of simulation techniques in the process of healthcare decision-making.
Merce` Comas
Epidemiology and Evaluation Department
Institut Hospital del Mar d’Investigacions Me`diques (IMIM)

Abstract
Colorectal cancer is the most common cancer in both men and women in Catalonia,
with more than 6,000 new cases each year. It also represents the second leading
cause of cancer death. For this reason a colorectal cancer screening program is
currently being extended to all Catalonia. The operational structure will consist
of various territorial technical offices that include one or more endoscopic units.
It is considered that the endoscopic units will assume both colonoscopies after a
positive screening fecal inmunochemical test and the colonoscopies for surveillance
of premalignant lesions detected in the colonoscopy after a positive FIT.
The aim of this project is to estimate the number of colonoscopies of both types
that every endoscopic unit will have to provide through a discrete event simulation
model, with a special focus on the probabilistic sensitivity analysis of the main
factors affecting the demand of colonoscopies.
This model simulates a time horizon of 20 years (from 2015 to 2034) to allow
a long term prediction of colonoscopy demand according to the program results.
Individual persons were simulated. All persons underwent biennial screening from
50 to 69 years of age. The conceptual model was based on the European Guidelines
for Colorectal Cancer Screening for both the screening process and the surveillance
after premalignant findings process. The model was fed mainly with data from the
first and second rounds of the “Barcelona Esquerra” and “Litoral Mar” Program
and applied to the Catalan population aged 50-69 predicted for the future years.
For the population of all Catalonia the model predicted a total number of colono-
scopies that increase from 21,286 in the first year, passing on 39.060 passed 10
years, to 45,319 after 20 years, making a total of almost 730,000 colonoscopies
during these 20 years according to the model predictions. Of these 730,000 colono-
scopies the 60% will be colonoscopies after a positive FIT, and 40% will be those
for the surveillance of the detected pre-malignant lesions.
Results of the sensitivity analysis showed that FIT positivity is far the most sensitive
variable. A change in a 1% of positivity has an impact similar to a 10% change
in participation. Adherence affects to the number of surveillance colonoscopies
only, and it is the variable with the lowest effect in magnitude, although its effect
increases with time.
In order to deliver these results for every endoscopic unit in a friendly user way, an
application was created using R software to present customized data for each unit.
This application can be useful for planning the necessary resources in a 20-year
horizon and will be presented to the Technical Screening Office of Catalonia.
iIn conclusion, this simulation model and its analysis have shown to be powerful
tools for health services planning and to inform decision-making. Beyond the mod-
elling/technical matters, this piece of research should facilitate reactions on the
capacity of the health system to meet the demand of colonoscopies induced by
the CRC screening program, and how endoscopy workforce should be subject to a
conscious planning.
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Cancer is a word, not a sentence
- John Diamond
1.1. About the problem
Colorectal cancer (also known as CRC for its acronym in English) is, in Spain and
specifically in Catalonia, the most common cancer in incidence and the second in
mortality, making it one of the most important to consider.
In this chapter we will do an introduction about the problem that this cancer
represents and the problem we want to face in this project.
Despite colorectal cancer is a cancer that kills a lot of people worldwide yearly, it
is true that this cancer has a low mortality if it is detected early, which makes very
important the population awareness of screening programs.
The colorectal cancer screening program is extended in Spain, where is already
implemented or piloted in all regions except in Castilla La Mancha. In Catalonia, it
was established in two regions, has been extended to all Catalonia during 2015, and
will be fully operative in 2016. This program it is focused to both men and women
aged between 50 to 69 and it based on a biennial fecal occult blood inmunochemical
test (FIT) and then a colonoscopy for positive ones.
With the extension of this screening program, arises the need of estimate the number
of colonoscopies, both after a positive FIT and for surveillance of premalignant
lesions detected, that every endoscopic unit will have to provide in the future for
being prepared for it.
This problem will be solved using a discrete event simulation model that predicts
the future demand of colonoscopies in each Endoscopic Unit of Catalonia in the
next 20 years, that will be explained on chapter 2.
Participation in the screening program, FIT positivity and adherence to surveillance
colonoscopies are crucial parameters in the model. All of them are included as
probabilistic parameters in the model. In order to assess how the uncertainty
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associated with the estimation of this three parameters affects the results of this
simulation model, a sensitivity analysis was performed and explained in chapter 3.
On chapter 4 it will be explained what are the next steps on this project and how
this model is being improved in order to be more accurate at predicting. Finally,
the discussion and conclusions of this dissertation will be included on chapter 5.
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1.2. A brief look to the epidemiology of CRC
All the data of incident, mortality and prevalence worldwide of colorectal cancer
that is presented on this section has been collected from the GLOBOCAN project
1 created by the International Agency for Research on Cancer (IARC) which aim
is to provide contemporary estimates of the incidence of, mortality and prevalence
from major types of cancer, at national level, for 184 countries of the world. The
data specifically from Spain and Catalonia is collected from the review “Las cifras
del ca´ncer 2014 2 that provided the Spanish Society of Oncology (SEOM)”.
Colorectal cancer is the development of cancer in the colon or rectum (parts of
the large intestine). It occurs due to abnormal growth of epithelial cells with the
ability to invade other parts of the body. Signs and symptoms may include blood
in the stool, a change in bowel movements, weight loss and fatigue. There are some
factors that increase the risk that a person develops the disease, including:
History of cancer. Individuals who have previously been diagnosed and treated
as having cancer have a higher risk of colorectal cancer than the general population
as well as for other cancers.
Heredity. Family history of colorectal cancer, especially a close relative less than
55 years or multiple relatives. Familial adenomatous polyposis, involves nearly
100% risk of developing colorectal cancer by the age of 40, unless it has been
treated. Lynch syndrome or colorectal cancer hereditary non-polyposis. Chronic
ulcerative colitis or Crohn’s disease, about 30% after 25 years if the entire colon is
affected 3.
Age. The risk of colorectal cancer increases with increasing age. Most cases occur
between 60 and 70 years, whereas before age 50 is rare, unless there is a family
history of early onset of colorectal cancer, particularly adenomatous polyps 4.
Smoke. It is more likely that a person who smokes die of colorectal cancer than
a non-smoking a person. The American Cancer Society did a study where it was
found that women who smoke are 40% more likely to die of colorectal cancer than
women who never smoked. Male smokers have a 30% higher risk of dying from the
disease than their non-smoking counterparts 5.
Diet. Studies show that a diet rich in meat and low in fruits, vegetables, poultry
and fish increases the risk of colorectal cancer. However, other studies cast doubt
on the claim that a diet high in fiber reduces the risk of colorectal cancer rather, the
relationship between dietary fiber and risk of colorectal cancer is still in debate. An
investigation by the European Prospective Investigation into Cancer and Nutrition
suggested that diets high in red meat, as well as those low in fiber, are associated
with a risk of colorectal cancer 6.
1 See Globocan
2 See Las cifras del ca´ncer 2014
3 See Lutgens M.W., van Oijen M.G., van der Heijden G.J. et al (2013)
4 See Cunningham D., Atkin W., Lenz H.J. et al (2010)
5 See Botteri E., Iodice S., Bagnardi V., et al (2008)
6 See Bouvard V., Loomis D., Guyton K.Z. et al (2015)
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Physical activity. Those who are physically active have a lower risk of developing
colorectal cancer 7.
Fig. 1.1. Estimated Colorectal Cancer incidence worldwide
Colorectal cancer was at 2012 the third most common cancer in men (746,000
cases, 10.0% of the total) and the second in women (614,000 cases, 9.2% of the
total) worldwide. Almost 55% of the cases occur in more developed regions. There
is wide geographical variation in incidence across the world and the geographical
patterns are very similar in men and women: incidence rates vary ten-fold in both
sexes worldwide, the highest estimated rates being in Australia/New Zealand (44.8
and 32.2 per 100,000 in men and women respectively), and the lowest in Western
Africa (4.5 and 3.8 per 100,000) as shown in figure 1.1 8.
Fig. 1.2. Estimated Colorectal Cancer mortality worldwide
7 See Giovannucci E., Ascherio A., Rimm E.B. et al (1995)
8 See Ferlay J., Soerjomataram I., Ervik M. et al (2013)
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Mortality is also lower in the less developed regions of the world, reflecting a poorer
survival in these regions. There is less variability in mortality rates worldwide (six-
fold in men, four-fold in women), with the highest estimated mortality rates in both
sexes in Central and Eastern Europe (20.3 per 100,000 for men, 11.7 per 100,000
for women), and the lowest in Western Africa (3.5 and 3.0, respectively) as shown
in figure 1.2 9.
Figure 1.3 shows 5 year prevalence proportions per 100,000 inhabitants. As in terms
of mortality and incidence, prevalence seems to be higher in the most developed
regions of the world 10.
Fig. 1.3. Estimated Colorectal Cancer prevalence worldwide
In Spain cancer is the second most common mortality cause (27.5% of deaths) just
below the circulatory system diseases. Colorectal cancer is the most common cancer
in terms of incidence and the second in terms of mortality if we look at both sexes.
Figure 1.4 shows the estimated incidence and mortality of the different cancers in
2012.
That year, 15,604 persons of the 107,012 that died of cancer in Spain, died for
colorectal cancer. Stratifying by sexes in terms of males is the third in incidence
after lung and prostate cancer and second in mortality after lung cancer. In women
is the second in incidence after breast cancer and the third in mortality after breast
and lung cancer.
9 See Ferlay J., Soerjomataram I., Ervik M. et al (2013)
10 See Bray F., Ren J.S., Masuyer E. et al (2012)
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Fig. 1.4. Estimated incidence and mortality for both sexes in Spain
The 5-year prevalence in Spain at 2012 was 581,688 cases with a rate of 1467.6 cases
per 100,000 inhabitants, 3 years prevalence was 389,498 and 1 year prevalence was
151,257 cases.
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1.3. Screening of colorectal cancer
Colorectal cancer is the most common cancer in all men and women in Catalonia,
with more than 6,000 new cases each year. As in all Spain, it also represents the
second leading cause of cancer death.
This cancer can be diagnosed by obtaining a sample of the colon during a sigmoi-
doscopy or colonoscopy. This is followed by medical imaging to determine whether
the disease has spread. As over 80 % of colorectal cancers arise from adenomatous
polyps, the screening of this cancer is effective not only for early detection, but also
for prevention. The diagnosis of colorectal cancer by screening tends can occur 2-3
years before the diagnosis of cases with symptoms. All polyps that are detected
can be removed, usually by colonoscopy, and so this prevents them from becoming
cancer cells.
The three main detection tests are fecal occult blood tests (FOBT), flexible sig-
moidoscopy and colonoscopy. Of the three, sigmoidoscopy is the only one that can
not detect the right side of the colon, where there are 42 % of malignant tumours
Virtual colonoscopy by CT scan is as good as standard colonoscopy for the detec-
tion of cancers and large adenomas, but is much more expensive, is associated with
exposure to radiation, and can not eliminate the detected abnormal growths as can
the standard colonoscopy.
FOBT is recommended every two years and may be guayac or inmunochemical. If
results are abnormal FOBT, participants are advised to do a colonoscopy. Inmuno-
chemical tests are very accurate and do not require changes in diet or medication
before the test as guayacs does.
The United States Preventive Services Task Force and ather medical societies rec-
ommends screening for colorectal cancer using fecal occult blood testing, sigmoi-
doscopy, or colonoscopy in adults, beginning at age 50 years and continuing until
age 75 years 11.
In Europe there is a guideline 12 about the process a patient has to follow when the
result of the FIT is positive. Besides negative and positive for cancer, it divides the
result of adenoma findings in 3 groups; low, intermediate and high risk depending
on the number and size of the adenomas. This guideline is shown on figure 1.5.
Some countries have national screening programs that offer FOBT to all adults
within a certain age group. Among them, in Spain the screening program is already
implemented or piloted in all regions except in Castilla La Mancha. Specifically,
the catalan program began in 2,000 and it includes people from 50 to 69 years old,
it currently uses FIT and is based on the european guidelines.
11 See U. S. Preventive Services Task Force.
12 See Segnan N., Patnick J., von Karsa L. (2010)
8 1. INTRODUCTION
Fig. 1.5. European Guidelines of the process of monitoring the ade-
noma findings of the colonoscopy after a positive FIT
The program in Catalonia is offered and managed in a decentralized manner. In
particular it is organized in 13:
Technical screening offices (OTC): Their function is the management,
monitoring and evaluation of the program in its territory: invitations man-
agement, coordination, collection and processing of screening tests, coordina-
tion of endoscopic units, activity monitoring and controlling and improving the
quality of the screening program. These offices must have a coordinator and
an adequate human team for the tasks to develop (professionals and experts
in public health and preventive medicine, support for management and data
analysis, administrative staff and other necessary staff). It is recommended
one technical office for each health care region (RS) of the 7 which conform
Catalonia, however due to the huge variation in population number between
RS, those with a small volume of target population will be able to share OTC.
Endoscopic units: These are the units that have to perform colonoscopies
for those positive cases of screening and other tests necessary for the diagnosis
process. There are actually 38 in Catalonia.
Pharmacies: Act as health workers, providing information, giving people the
kit and monitoring the storage and shipment of the sample to the laboratory.
13 See Generalitat de Catalunya
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The team of primary healthcare : They have an important role in the
program and in the dissemination of information and advice about the program
and early detection of cancer.
Technical screening office of Catalonia: Serving to define and ensure the
application of the common organization of quality criteria and evaluation, co-
ordinating the activities of the various OTC, developing a common system of
minimum information that allows planning and evaluation of screening pro-
grams, assess the impact and results and finally propose corrective actions to
improve quality and results.
The process of this program works as follows:
The OTC invites men and women between 50 and 69 years, through a letter sent
to their address, to participate in the program.
The letter includes the device to collect stool sample or it is indicated where they
can pick it up, either in the pharmacy or in the primary care centre. Once the
samples is collected, it is returned by the patient, they return the samples by the
means indicated and samples are analysed in a laboratory. In the event that the test
is negative, i.e., that there are not traces of blood in the stool, or a concentration
of blood below a determined threshold, a letter with the result is sent and the next
invitation is issued after 2 years.
If the result is positive a colonoscopy is recommended to find out the possible causes
of bleeding. Not all bleeding is due to cancer, most are due to other benign lesions.
Depending on the outcome, the health care follow up will differ.
The Catalan program will be finally extended in 2016. The areas of “Barcelona
Esquerra” and “Litoral Mar” began in 2009. Parameters of the present model are
mainly based on of the first and second rounds of this areas.
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1.4. Discrete event simulation
The science of simulation allows us to create new modelling methodologies that
analyse complex systems through virtual experimentation for use to measure the
impact of complex interventions in health services. Discrete-event simulation is
a technique already known in operations research, that has been used in military
research and manufacturing systems. In the context of health care, Markov models
and decision trees have been used for several years, but they have many limitations
to reproduce health problems, so the discrete-event simulation is used every day
more in this area.
Markov models is conceptualized in terms of “states” and “transitions ”. A patient
can move from one state (this states can reproduce de health status of patient) to
another, but these states are always discrete.
So it arises the need of a type of simulation which each state that represents the
health status of the patient is measured by attributes, thus can be continuous or
discrete, and here appears discrete-event simulation.
Discrete-event simulation has been defined as a flexible modelling method char-
acterized by the ability to represent complex behaviours, interactions within and
between individuals, populations and their environments.
You can also represent all the features of a real system, as facilities or resources.
Moreover, although changes in the system are discrete, they occur on a continuous
time scale, as each event is scheduled to happen at a time value drawn a continuous
random distribution
Besides discrete-event simulation has a specific tool; the queues, that allows us to
model a waiting list which can not be done with Markov models. Furthermore
individual characteristics of each patient are simulated more straightforward with
discrete event simulation.
Speaking of the model output, the output of the discrete-event simulation models
is not only survival by state as Markov models, but also incidence, prevalence and
evolution of health states through the time horizon of the simulation. Moreover,
any simulation output can be reported at any time up to the time horizon, not just
at the end as in Markov models. Furthermore, Markov models prior information
is lost because of the Markov’s assumption, that causes that only the current state
is taken into account. In our discrete event simulation models, using events rather
than states, dependence on prior events may be included, therefore the Markov’s
assumption is overcome.
If we use the discrete-event simulation models to analyse need and demand in
terms of health services it is important to calculate the incidence and prevalence
in the population all the time, taking into account survival of the population and
that cohorts are dynamic, with entries and exits of individuals through time.. By
contrast, the Markov models analyse patients in the initial cohort . The key point
in the evaluation of health services is the prevalence of disease and the availability
and consumption of resources over time. The resource capacity to meet the needs
and demands is limited and there may be queues. As said before we can also analyse
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waiting list that are a particular type of queue, patients are not physically lining
up for the service, but are waiting to receive the medical service.
In summary, discrete event simulation was chosen to solve the present problem
because a dynamic cohort, with entries and exits of entities (persons) through
time was needed, because the paths of entities within the system were complex and
because of the relevance of adjusting the results to the predicted population ageing.
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1.5. Aim and objectives of this work
The aim and objectives we will seek in this project are:
Aim:
Define a mathematical model to analyse through simulation the future demands
of colonoscopies that has to provide each endoscopies unit to carry out the
program for early detection of colorectal cancer throughout Catalonia
Objectives:
Verify and validate the previous model.
Make a sensitivity analysis to assess the impact of changing the participation of
the population, the FIT positivity and adherence to surveillance colonoscopies,
using a model and validating it.
Define an application to predict the number of colonoscopies based on this three
variables, with the model the models estimated in sensitivity analysis.
Chapter 2
Simulation model
All models are wrong,
but some are useful
- George E.P. Box 1
To create a discrete event model we have to go through three stages.
First step we need to do before build the model is a process of observation of system
in order to learn about the matter we are going to analyse.
This knowledge should then be reflected in a conceptual model, in which each
member of this integrated model, events to occur as well as subjects, attributes
and variables have to be estimated. It has to be included a definition of each
component of the model, i.e., the events of the process studied, subjects, their
attributes and parameters to be estimated. The study population must also be
defined, as the level of detail and scope of the model.
The second step is to estimate the parameters that are needed to characterize the
model given our ability to transform our conceptual model in a computational
model that will be the next step. To do this we need to collect the necessary data
for the estimation of these parameters.
As stated previously the third step is to translate the conceptual model into a
computed model. We have to take care about the complexity of health systems
because we’re trying to model discrete events occurring at any point in time.
In this chapter I will explain briefly the model that was used and the validation of
it.
1 See Box, G.E.P., Draper N. R. (1987)
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2.1. Conceptual Model
This model has two stages; the screening process and the surveillance of adenomas.
The events that this model simulated were: Inclusion of a new person in the target
population, exclusion process, invitation process, participation process, result of the
FOBT test, colonoscopy after a positive FOBT test and surveillance colonoscopy.
The exits of the model were detection of invasive CRC, death or exclusion from the
target population. Individuals under surveillance through colonoscopy had an age
limit of 80 years.
Fig. 2.1. Conceptual model of the screening process
In figure 2.1 we can see the conceptual model of the screening process. There
were five different cases where individuals were invited to the program after two
years: opportunistic screening through colonoscopy 5 years ago, no participation,
participation with a negative FIT, a positive FIT and colonoscopy refusal or findings
of low-risk adenomas.
Individuals were invited after 4 years if they had a colonoscopy (opportunistic
screening) 3 years ago, while those with a negative result of the colonoscopy after a
positive FIT were invited after 10 years to routine screening. Colonoscopy results
of high- or intermediate-risk adenomas entered the path of surveillance through
colonoscopy.
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Fig. 2.2. Conceptual model of the surveillance process
The conceptual model of surveillance of adenomas is adapted from European guide-
lines as shown in figure 1.5, the adaptation of those criteria to our model is shown
in figure 2.2. If the result of the colonoscopy after a positive FIT is LRA (Low risk
adenomas), routine screening through FIT after 2 years is recommended, and begin
again the screening process.
If the result of the colonoscopy after a positive FIT is IRA(Intermediate risk ade-
nomas) or HRA ( High risk adenomas) a surveillance colonoscopy is recommended
after 3 and 1 years, respectively. The intensity of surveillance colonoscopies (after
1, 3 or 5 years) will depend on the result of every colonoscopy as shown in figure
2.2.
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2.2. Techniques
The simulation model was implemented by using Arena (Rockwell Software) version
14.5.
At the beginning of the simulation the target population was 100,000 men and
women aged 50-69 years undergoing biennial screening. From the second year on,
persons aged 50 years old entered the ¡following current predictions on Catalan
population. Persons aged 68-69 were excluded after their last screening round.
A total of 1,750 replications of the model with independent streams of random
numbers were run. The time units were years. A time horizon of 20 years (from
2015 to 2034) was chosen to simulate the life history of a person entering a screening
program (from 50 to 69 years) and to allow long term prediction of colonoscopy
demand according to the program results. Individual persons from 50 to 69 years
of age were simulated. Persons aged 70 years or older were followed-up until 79
years of age only if they were having surveillance colonoscopies, if not were taken
off the study. The entire population involved in the system each year was included.
Thus, individual people entering and exiting the model were simulated throughout
the simulation horizon.
This model takes into account the ageing of the population in the following way.
An initial population was introduced. The model starts in 2015 with the population
structure of the actual target population of Catalonia which is shown in Figure 2.3,
upscaling to 100,000 inhabitants.
Fig. 2.3. Target population of Catalonia
Since the start of the simulation every year enters in the model the new population
that turns fifty years old. From 2015-2029 these data for Catalonia can be found
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in INEbase 2 , from 2029-2034 the Spanish prediction was used also of INEbase
applying it to the Catalan population. This data is shown on figure 2.4.
Fig. 2.4. Prediction of 50 year old population of Catalonia
Data of the first and second rounds of a Spanish CRC Screening Program includ-
ing 31 geographical areas was used to calculate the parameters related to screen-
ing. Percentage of exclusions, opportunistic screening, participation, positivity
colonoscopy refusal and adherence were treated as probabilistic parameters, last
one was the unique that was constant for each run. As this parameters clearly
differ significantly by age groups and gender, different distributions were estimated
for each parameter and for strata combining four different groups of age (50-54,
55-59, 60-64 and 65-69) and gender.
The models used to estimate those parameters were of the form:
A+B · beta(α, β) ; A,B ∈ R ; α, β > 0
We can see the parameters used in figure 2.5
Beta distribution was selected due to this distribution is appropriate to adjust
probabilities because it take values between 0 and 1, and the A and B parameters
are used to rescale it .
This values of the betas distribution used to estimate the parameters were calculated
using the data of the first (2009-2011), second (2011-2013) and third (2013-2015)
rounds of the Colorectal Cancer Screening Program of Barcelona and the software
“Input Analyzer ” of Arena.
2 See INEbase
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Fig. 2.5. Models used to estimate the parameters
Table 2.1. Distribution of results from colonoscopy after a positive FIT
Initial Successive
screening (%) screening (%)
Negative 32.0 41.9
Low risk adenoma 17.1 20.4
Intermediate adenomas 28.2 25.6
High risk adenoma 16.6 9.0
Cancer 6.1 3.1
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Distribution of the results of the colonoscopy after a positive FIT for initial screen-
ing were obtained from the first round of the this program. For successive screening
the results were obtained from the second round, by analysing those individuals that
had a negative FIT in the first round. It is shown on table 2.1
Table 2.2. Distribution of results from surveillance colonoscopy
After high risk adenomas After intermediate risk adenomas
1 year 3 years 3 years
Negative 72.48 78.40 67.99
Low risk adenoma 24.95 20.41 28.27
Intermediate
and high risk 2.57 0.89 3.27
adenoma
Cancer 0 0.30 0.47
In table 2.2 we can see the distribution of results from surveillance colonoscopy
according to follow-up time and result of the colonoscopy after the positive fe-
cal inmunochemical test. This distribution was obtained from Winawer et al. 3,
considering those labelled as “pathologically advanced adenomas”as of high or in-
termediate risk, the rest of adenomas as low risk,invasive cancer as is, and the rest
of colonoscopies as negative. For follow-up after the first surveillance colonoscopy,
results of high or intermediate risk were considered as of high risk in the scheme.
For follow-up at 5 years, results of 3-years follow-up were applied according to the
risk obtained in the colonoscopy after a positive FIT.
3See Winawer S.J., Zauber A.G., O’Brien M.J. et al (1993)
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2.3. Verification and validation
For validation purposes, a subgroup of runs representing the current scenario was
analysed. This group included 393 runs and was defined as mean 20-year partici-
pation between 40% and 60%, mean 20-year FIT positivity between 4.7% and 6.8%
and adherence to surveillance colonoscopies between 35% and 70%. This group of
393 runs was used for the main analysis of this study.
The following results were used to validate the model: the number of invited people
through time (by initial and successive screenings), the participation rate, positivity
of FIT (by initial and successive screenings), the number of colonoscopies over time
(by initial and successive screenings), distribution of colonoscopy findings (by initial
and successive screenings), and life expectancy. Validation results were checked by
the research team and the model was considered as valid, credible and useful for
the purposes of the study.
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2.4. Results
Table 2.3 shows that biennial screening of an initial population of 100,000 men and
women led to a mean of more than 40,000 colonoscopies both after a positive FIT
and for surveillance during the 20-year horizon.
Table 2.3. Average results of 20 years of screening
Year Colonoscopies Surveillance All
after positive FIT colonoscopies colonoscopies
2015 1222 [1212,1231] 0 [0,0] 1222 [1212,1231]
2016 1221 [1211,1232] 180 [179,181] 1401 [1390,1413]
2017 1119 [1108,1130] 184 [183,185] 1303 [1291,1315]
2018 1110 [1100,1120] 458 [451,461] 1568 [1551,1581]
2019 1171 [1157,1184] 626 [622,630] 1797 [1779,1814]
2020 1165 [1152,1178] 609 [604,613] 1774 [1756,1791]
2021 1178 [1166,1190] 816 [811,821] 1994 [1977,2011]
2022 1190 [1179,1201] 878 [871,885] 2068 [2050,2086]
2023 1213 [1200,1225] 869 [862,876] 2082 [2062,2101]
2024 1231 [1217,1244] 994 [987,1001] 2225 [2204,2245]
2025 1246 [1233,1260] 1007 [999,1015] 2253 [2232,2275]
2026 1274 [1259,1289] 1051 [1042,1059] 2325 [2301,2348]
2027 1303 [1288,1317] 1082 [1074,1090] 2385 [2362,2407]
2028 1319 [1304,1333] 1084 [1074,1094] 2403 [2378,2427]
2029 1332 [1317,1346] 1117 [1107,1126] 2449 [2424,2472]
2030 1327 [1313,1342] 1138 [1128,1148] 2465 [2441,2490]
2031 1366 [1351,1381] 1198 [1186,1209] 2564 [2537,1339]
2032 1373 [1358,1388] 1209 [1197,1121] 2582 [2555,2509]
2033 1385 [1369,1401] 1209 [1198,1220] 2594 [2567,2621]
2034 1376 [1361,1391] 1238 [1227,1249] 2614 [2588,2640]
Total 25121 16947 42068
Table 2.4. Average participation and positivity of 20 years of screening
Year Participation Positivity
2015 43.9 % 6.7 %
2016 43.8 % 6.7 %
2017 47.4 % 5.3 %
2018 47.4 % 5.3 %
2019 49.1 % 5.3 %
2020 49.0 % 5.2 %
2021 49.7 % 5.1 %
2022 49.7 % 5.1 %
2023 50.1 % 5.0%
2024 50.1 % 5.1%
2025 50.3 % 5.0%
2026 50.3 % 5.0%
2027 50.4 % 5.0%
2028 50.4 % 4.9%
2029 50.5 % 4.9%
2030 50.6 % 4.9%
2031 50.6 % 4.9%
2032 50.7 % 4.9%
2033 50.7 % 4.9%
2034 50.8 % 4.9%
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Yearly results show an increase in the number of surveillance colonoscopies, al-
though positivity, as a percentage, decreased through time. This colonoscopies had
a mean adherence of 52.058%.
Fig. 2.6. Participation and positivity through time
Figure 2.6 and table 2.4 shows variations in mean participation and mean positivity
through time. The first two years represent the first round of the program and
show higher positivity and lower participation because all participants are of initial
screening. Afterwards, the increasing number of successive screenings impacts on
an increasing participation rate and a decreasing positivity, both stabilizing at the
long term.
Fig. 2.7. Number of colonoscopies through time
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The main outcome of this study is the number of colonoscopies needed for both the
screening program and the surveillance of non-cancer findings.
Figure 2.7 shows in stacked bars the number of colonoscopies: below, those after
a positive FIT, above, the number of surveillance colonoscopies, which show a
sharper increase beginning at the second year. Overall number of colonoscopies
doubled after 14 years (2028).
In addition the number of surveillance colonoscopies through time is also shown
by the orange line, facilitating comparison between the number of colonoscopies
according to their type. The result is that the number of colonoscopies after a
positive FIT is always higher than the number of surveillance colonoscopies, but





As the man said, for every complex problem
there is a simple solution,
and it’s wrong.
- Umberto Eco 1
In order to assess how the uncertainty associated with the estimation of the par-
ticipation, FIT positivity and adherence to surveillance colonoscopies affects the
results of this simulation model, a sensitivity analysis was performed.
The first idea was to create two mixed effects models using the number of colono-
scopies after a positive FIT and the number of surveillance colonoscopies as response
variables to see the effect of an increase or decrease of those three variables through
time. This models were selected because they can represent the variability among
simulations placing a random effect in the intercept, and the variability through
time adding a random effect on the time.
Literature was consulted and any article that apply this technique for a sensitivity
analysis was found, so it could be an innovation in terms of techniques to consider.
However, it turned out that with these data these models were not able to be used,
as any model found verified the hypothesis of the models, specifically the hypothesis
of normality of the errors, neither changing the model nor applying transformations
to the variables. So it was decided to adapt the sensitivity analysis using a linear
model for each year and each type of colonoscopy (to a total of 40 models), which
met its purpose and that verified the previous assumptions.
1See Eco U. (1989)
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3.1. Mixed Effects Models (ME)
A mixed effects model is a statistical model containing both fixed effects and random
effects. They are particularly useful in settings where repeated measurements are
made on the same statistical units (longitudinal study), or where measurements are
made on clusters of related statistical units.
In matrix notation a mixed model can be represented as
y = Xβ + Zb+ 
where
y is a known vector of observations, with mean E(y) = Xβ;
β is an unknown vector of fixed effects;
b is an unknown vector of random effects, with mean E(b) = 0 and variance-
covariance matrix var(b) = G;
 is an unknown vector of random errors, with mean E() = 0 and variance
var()=R;
X and Z are known design matrices relating the observations y to β and b,
respectively.
It has several assumptions that must be met
Linearity. The regression function is linear.
Homocedasticity. The errors variance is constant.
Normality of errors. The errors are normally distributed.
Independence of errors. The random variables representing errors ”1, · · · , n”
are mutually independent.
Normality of random effects. The random effects are normally distributed.
Usually it is used to model several individuals with several measures on a variable,
in this case we will use them as if each simulation its an individual and we take
20 measures, one per year, that will be the means of the variables participation,
positivity and adherence of the run. The objective is to model the number of
screening or surveillance colonoscopies made that year in terms of the variables
adherence, positivity and participation. We have estimated the parameters with
the R software version 3.2.2.
3.1.1. ME model for the number of colonoscopies after a positive FIT.
For the number of colonoscopies after a positive FIT, the model used has random
effects at the intercept and at the variable time and fixed effects at the intercept, the
variable time, positivity, participation and both interactions between positivity and
participation with time, to find out whether the effect of positivity and participation
is different through time, because we understand that the effect of one of this
variables over the response variable will depend of the value of the other one.
The results are:
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Intercept: β0 = −957.24
Coefficient of time: β1 = −5.58
Coefficient of positivity: β2 = 172.93
Coefficient of participation: β3 = 22.62
Coefficient of interaction between time and positivity: β12 = 3.35




Number of colonoscopies after a positive FIT at time t: Nt
Years since start of simulation: t ∈ (1, 20)
Positivity: PO
Participation: PA











On figure 3.1 we can see the distribution of the random effects
In this sensitivity analysis we want to estimate the effect of an increase of a 1% on
positivity or participation on the response variable. Thus, we will be interested on
this variables:











β0 + b0i + (β1 + b1i) · t+ β2 · x+β3 · PA+ β12 · x · t+((((((β13 · PA · t) =
=β2 · x+ β2 +β12 · x · t+ β12 · t−β2 · x−β12 · x · t =
= β2 + β12 · t
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Fig. 3.1. Random effects of the mixed effects model













β0 + b0i + (β1 + b1i) · t+ β2 · PO + β3 · x+(((((β12 · PO · t+ β13 · x · t =
=β3 · x+ β3 +β13 · x · t+ β13 · t−β3 · x−β13 · x · t =
= β3 + β13 · t
As we have the correlations we can compute the confidence intervals as follows:
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Table 3.1. Sensitivity analysis with the ME Model
Increase of colonoscopies Increase of colonoscopies
after a positive FIT after a positive FIT
Year for an increase for an increase
of a 1% in positivity a 1% in participation
[IC95%] [IC95%]
2015 176.3 [173.8,178.7] 22.8 [22.5,23.0]
2016 179.6 [177.1,182.2] 22.9 [22.6,23.1]
2017 183.0 [180.3,185.7] 23.0 [22.8,23.3]
2018 186.3 [183.6,189.1] 23.1 [22.9,23.4]
2019 189.7 [186.9,192.5] 23.3 [23.0,23.5]
2020 193.0 [190.2,195.9] 23.4 [23.1,23.6]
2021 196.4 [193.5,199.3] 23.5 [23.3,23.7]
2022 199.8 [196.9,202.6] 23.6 [23.4,23.9]
2023 203.1 [200.3,205.9] 23.8 [23.5,24.0]
2024 206.5 [203.7,209.2] 23.9 [23.6,24.1]
2025 209.8 [207.1,212.5] 24.0 [23.8,24.2]
2026 213.2 [210.6,215.7] 24.1 [23.9,24.4]
2027 216.5 [214.1,219.0] 24.2 [24.0,24.5]
2028 219.9 [217.6,222.2] 24.4 [24.1,24.6]
2029 223.2 [221.0,225.4] 24.5 [24.2,24.8]
2030 226.6 [224.5,228.7] 24.6 [24.3,24.9]
2031 229.9 [228.0,231.9] 24.7 [24.5,25.0]
2032 233.3 [231.4,235.2] 24.9 [24.6,25.1]
2033 236.6 [234.9,238.4] 25.0 [24.7,25.3]
2034 240.0 [238.3,241.7] 25.1 [24.8,25.4]
2035 243.3 [241.7,244.9] 25.2 [24.9,25.5]
As we can see for table 3.1, a change in 1% in positivity changes substantially
the number of colonoscopies after a positive FIT per 100,000 inhabitants, and this
change increases over time. It will increase in 176.3 colonoscopies in 2015, 209.8 in
2024 and 240.0 in 2034.
On the other hand an increase of a 1% of the participation will increase in almost
23 the number of colonoscopies after a positive FIT in the first year, showing a
slight increase to 25 colonoscopies in 2034.
3.1.2. Validation of Mixed effects models.
To validate if this model is correct, we will we will check the assumptions of the
mixed effects model. As it is shown in the qqplot, figure 3.2, the residuals of our
model are not normally distributed. Let’s compute a normality test to verify it.
> lillie.test(lme.1$residuals[,1])
Lilliefors (Kolmogorov-Smirnov) normality test
data: lme.1$residuals[, 1]
D = 0.054787, p-value < 2.2e-16
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Fig. 3.2. QQplot of the mixed effects model residuals
As supposed by the qqplot, the residuals of this model are not normally distributed,
hence, this model is not valid. A great number of transformations (square root,
logarithm, box cox, · · · ) where tried to see if normalizing the data we could fix
this problem, but it was impossible, so it arises the need of using another type of
models, in this case the simple linear regression.
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3.2. General Linear Model (LM)
In general terms the general linear model is similar to the mixed effects one, but in
the LM we use fixed effects only instead of fixed and random.
In matrix notation a general linear model can be represented as
y = Xβ + 
where
y is a known vector of observations, with mean E(y) = Xβ;
β is an unknown vector of fixed effects;
 is an unknown vector of random errors, with mean E() = 0 and variance
var()=R;
X is a known design matrix relating the observations y to β.
It has 4 assumptions that must be met
Linearity. The regression function is linear.
Homocedasticity. The error variance is constant.
Normality. The error is normally distributed.
Independence. The random variables representing errors ”1, · · · , n” are
mutually independent.
Thus, 40 models where computed, one for each year and each type of colonoscopy.
3.2.1. Advantages and disadvantages of LM vs ME.
These models have advantages and disadvantages with respect to the mixed effects
models.
Disadvantages
• This models are simpler than the mixed effects models and do not use
random effects, so they do not take into account the variability within
subjects, in this case between simulations.
• Instead of computing 2 models we have to compute 40
Advantages
• Doing one model for each year makes that the prediction is much more
accurate.
• Despite of computing 20 times more models, the runtime of computing this
models is substantially lower
3.2.2. Linear Model for the number of colonoscopies after positive FIT.
Let:
NScreening: Number of colonoscopies after a positive FIT
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β0: Intercept
PA: Participation
β1: Coefficient of participation:
PO: Positivity
β2: Coefficient of positivity
β12: Coefficient of the interaction between positivity and participation:
We will adjust models with the following structure:
NScreening = β0 + PA · β1 + PO · β2 + PA · PO · β12
In the same way than in mixed effects model our estimate of the increase in the
number of colonoscopies after a positive FIT for a 1% increase in positivity with a
participation of PA will be:
β2 + PA · β12
Which variance will be:
V ar(β2 + PA · β12) = V ar(β2) + PA2 · V ar(β12) + 2 · PA · Cov(β2, β12)
and confidence intervals:
IC95% = β2 + PA · β12 ± 1.96 · (V ar(β2 + PA · β12)/n) 12
On the other hand our estimate of the increase in the number of colonoscopies after
a positive FIT for a 1% increase in participation with a positivity of PO will be:
β1 + PO · β12
Which variance will be:
V ar(β1 + PO · β12) = V ar(β1) + PO2 · V ar(β12) + 2 · PO · Cov(β1, β12)
and confidence intervals:
IC95% = β1 + PO · β12 ± 1.96 · (V ar(β1 + PO · β12)/n) 12
In the table 3.2 we can see the values of this coefficients for the 20 models
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Table 3.2. Coefficients of regression
Year β0 β1 β2 β12
2015 -6 0.3673 1.7904 4.0849
2016 25.5827 -0.4208 -4.5877 4.272
2017 -40.6472 0.9674 6.9964 4.2118
2018 -61.3547 1.4881 13.7298 4.0874
2019 -16.7071 0.4694 4.6533 4.4371
2020 16.5079 0.1905 -1.8505 4.5016
2021 -1.7479 0.7778 6.9669 4.387
2022 -64.5311 2.0108 18.0132 4.1977
2023 -13.7993 1.1154 9.6662 4.4718
2024 -42.0731 1.9162 14.82 4.3627
2025 65.5724 -0.4867 -4.9494 4.9344
2026 8.0693 1.0353 9.1515 4.6409
2027 28.2684 0.4076 1.4362 4.9709
2028 -14.0557 1.3078 9.7122 4.8464
2029 10.1986 1.1901 7.744 4.9061
2030 -22.0543 1.524 16.0019 4.8157
2031 5.5452 1.0709 10.4677 4.9979
2032 -44.2581 2.115 19.2061 4.8257
2033 -0.1785 1.1892 9.3565 5.0821
2034 46.219 0.3501 1.7562 5.236
In the tables 3.3 and 3.4 we can see the increase of colonoscopies after a positive
FIT when we change the variables, through time and for a population of 100,000
inhabitants.
Table 3.3. Increase of colonoscopies after a positive FIT conditioned
on positivity
Increase of Increase of Increase of
colonoscopies colonoscopies colonoscopies
after positive FIT after positive FIT after positive FIT
YEAR for an increase for an increase for an increase
of a 1% in positivity of a 1% in positivity of a 1% in positivity
with a participation with a participation with a participation
of 40% of 50% of 60%
2015 165.2 [165.0,165.3] 206.0 [205.9,206.1] 246.9 [246.8,247.0]
2016 166.3 [166.1,166.4] 209.0 [208.9,209.1] 251.7 [251.6,251.8]
2017 175.5 [175.3,175.6] 217.6 [217.5,217.7] 259.7 [259.6,259.8]
2018 177.2 [177.1,177.4] 218.1 [218.0,218.2] 259.0 [258.9,259.1]
2019 182.1 [182.0,182.3] 226.5 [226.4,226.6] 270.9 [270.8,271.0]
2020 178.2 [178.1,178.4] 223.2 [223.1,223.4] 268.2 [268.1,268.3]
2021 182.4 [182.3,182.6] 226.3 [226.2,226.4] 270.2 [270.1,270.3]
2022 185.9 [185.8,186.1] 227.9 [227.8,228] 269.9 [269.8,270.0]
2023 188.5 [188.4,188.7] 233.3 [233.1,233.4] 278.0 [277.9,278.1]
2024 189.3 [189.2,189.5] 233.0 [232.8,233.1] 276.6 [276.5,276.7]
2025 192.4 [192.3,192.6] 241.8 [241.6,241.9] 291.1 [291.0,291.2]
2026 194.8 [194.6,194.9] 241.2 [241.1,241.3] 287.6 [287.5,287.7]
2027 200.3 [200.1,200.4] 250.0 [249.9,250.1] 299.7 [299.6,299.8]
2028 203.6 [203.4,203.7] 252.0 [251.9,252.2] 300.5 [300.4,300.6]
2029 204.0 [203.8,204.1] 253.0 [252.9,253.2] 302.1 [302.0,302.2]
2030 208.6 [208.5,208.8] 256.8 [256.7,256.9] 304.9 [304.8,305.0]
2031 210.4 [210.2,210.5] 260.4 [260.2,260.5] 310.3 [310.2,310.4]
2032 212.2 [212.1,212.4] 260.5 [260.4,260.6] 308.7 [308.6,308.8]
2033 212.6 [212.5,212.8] 263.5 [263.3,263.6] 314.3 [314.2,314.4]
2034 211.2 [211.0,211.4] 263.6 [263.4,263.7] 315.9 [315.8,316.0]
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Table 3.4. Increase of colonoscopies after a positive FIT conditioned
on participation
Increase of Increase of Increase of
colonoscopies colonoscopies colonoscopies
after positive FIT after positive FIT after positive FIT
YEAR for an increase for an increase for an increase
of a 1% in participation of a 1% in participation of a 1% in participation
with a positivity with a positivity with a positivity
of 4% of 5% of 6%
2015 16.7 [15.4,18.0] 20.8 [19.7,21.8] 24.9 [24.0,25.8]
2016 16.7 [15.4,18.0] 20.9 [19.9,22.0] 25.2 [24.3,26.1]
2017 17.8 [16.4,19.2] 22.0 [20.9,23.2] 26.2 [25.3,27.2]
2018 17.8 [16.5,19.2] 21.9 [20.8,23.1] 26.0 [25.1,27.0]
2019 18.2 [16.9,19.6] 22.7 [21.5,23.8] 27.1 [26.2,28.0]
2020 18.2 [16.8,19.5] 22.7 [21.6,23.8] 27.2 [26.3,28.1]
2021 18.3 [16.9,19.7] 22.7 [21.5,23.9] 27.1 [26.1,28.1]
2022 18.8 [17.5,20.1] 23.0 [21.9,24.1] 27.2 [26.3,28.1]
2023 19.0 [17.6,20.4] 23.5 [22.3,24.6] 27.9 [27.0,28.9]
2024 19.4 [18.0,20.7] 23.7 [22.6,24.9] 28.1 [27.1,29.0]
2025 19.3 [17.9,20.6] 24.2 [23.1,25.3] 29.1 [28.2,30.1]
2026 19.6 [18.2,21.0] 24.2 [23.1,25.3] 28.9 [27.9,29.8]
2027 20.3 [18.9,21.6] 25.3 [24.2,26.4] 30.2 [29.3,31.2]
2028 20.7 [19.4,22.0] 25.5 [24.4,26.6] 30.4 [29.5,31.3]
2029 20.8 [19.5,22.1] 25.7 [24.6,26.8] 30.6 [29.7,31.5]
2030 20.8 [19.4,22.1] 25.6 [24.5,26.7] 30.4 [29.5,31.3]
2031 21.1 [19.7,22.4] 26.1 [25.0,27.1] 31.1 [30.2,32.0]
2032 21.4 [20.1,22.8] 26.2 [25.1,27.4] 31.1 [30.1,32.0]
2033 21.5 [20.2,22.8] 26.6 [25.5,27.7] 31.7 [30.8,32.6]
2034 21.3 [20.0,22.6] 26.5 [25.4,27.6] 31.8 [30.8,32.7]
As we can see an increase of a 1% in the positivity increases substantially the
number of colonoscopies after a positive FIT, and this increase is higher through
time, and higher as the participation increases
On the other hand we can see that a increase of a 1% in the participation increases
the number of colonoscopies, but this changes are more or less 10 times smaller
than in terms of Positivity, so we can see that more or less increasing the positivity
in a 1% has the same effect that increasing participation in a 10%.
3.2.3. Linear Model for the number of surveillance colonoscopies.
As the model for the number of surveillance colonoscopies is more complex, we
would use the backward method to create the models. We will begin with all
the possible variables and interactions and for each time we will remove the less
significant variable until we have the model with the minimum AIC and which
verify all the assumptions of the linear model. Let:
NSurvei: Number of surveillance colonoscopies
β0: Intercept
PA: Participation
β1: Coefficient of participation
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PA2: Squared participation
β11: Coefficient of participation to square
PO: Positivity
β2: Coefficient of positivity
PO2: Squared positivity
β22: Coefficient of positivity to square
AD: Adherence
β3: Coefficient of adherence
β12: Coefficient of the interaction between participation and positivity
All our models have the following structure, but some will not have significance
in all the covariables. The interaction between positivity and adherence and the
interaction between adherence and participation have no sense (are not reflected
in the model we created). Moreover, the square of the adherence is not included
because it was not significant in either model.
NSurvei = β0 + PA · β1 + PO · β2 +AD · β3 + PA2 · β11+
+PO2 · β22 + PA · PO · β12
Our estimate of the increase of the number of surveillance colonoscopies when the
positivity increases from x to x+1 % with a participation PA will be:
 β0 +
PA · β1 + (x+ 1) · β2 +AD · β3 +PA2 · β11 + (x+ 1)2 · β22+
+PA · (x+ 1) · β12
− β0 −PA · β1 − x · β2 −AD · β3 −

PA2 · β11 − x2 · β22−
−PA · x · β12 =
= β2 + (2x+ 1) · β22 + PA · β12
which variance will be:
V ar(β2 + (2x+ 1) · β22 + PA · β12) =
= V ar(β2)+V ar((2x+1)·β22)+V ar(PA·β12)+Cov(β2, (2x+1)·β22)+Cov(β2, PA·β12)+
+Cov((2x+ 1) · β22, PA · β12) =
= V ar(β2)+(2x+1)
2 ·V ar(β22)+PA2 ·V ar(β12)+(2x+1)·Cov(β2, β22)+PA·Cov(β2, β12)
+PA · (2x+ 1) · Cov(β22, β12)
and so the following confidence intervals:
IC95% = β2 + (2x+ 1) · β22 + PA · β12 ± 1.96 · (V ar(β2 + (2x+ 1) · β22 + PA · β12)/n)
1
2
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The values of this coefficients for the 20 models are shown on table 3.5
Table 3.5. Coefficients of regression
Year β0 β1 β2 β12 β3 β11 β22
2016 -102.95 4.10 15.31 0 -0.05 0 0
2017 74.96 0.27 -9.01 0.55 0.08 0 0
2018 195.90 0.39 -28.33 1.56 -0.01 0 0
2019 154.6 0 0 0 0.47 0.1048 5.67
2020 163.99 1.12 -31.40 1.97 0.16 0 0
2021 156.46 2.1 -31.66 2.65 1.08 0 0
2022 42.06 4.11 -16.12 2.36 1.96 0 0
2023 -454.37 15.74 87.45 0 1.37 0 0
2024 125.1 0 0 0 2.86 0.17 9.49
2025 -672.69 18.73 117.65 0 2.91 0 0
2026 99.23 0 0 0 3.27 0.17 10.95
2027 -58.38 4.78 -17.9066 3.2 4.35 0 0
2028 -44.4 4.72 -23.87 3.14 4.29 0 0
2029 141.69 0.41 -60.81 4.08 4.48 0 0
2030 -859.87 20.75 139.27 0 4.63 0 0
2031 30.66 3.06 -42.35 3.81 4.93 0 0
2032 -891.88 21.65 146.15 0 5.14 0 0
2033 55.48 2.31 -48.09 4.01 5.09 0 0
2034 -982.63 22.67 150.79 0 5.81 0 0
Table 3.6. Increase in the number of surveillance colonoscopies by in-
creasing positivity
Increase of Increase of Increase of
surveillance surveillance surveillance
colonoscopies colonoscopies colonoscopies
YEAR for an increase for an increase for an increase
from 4% to 5% from 4% to 5% from 4% to 5%
in positivity in positivity in positivity
with a participation with a participation with a participation
of 40% of 50% of 60%
2016 15.3 [13.8,16.8] 15.3 [13.8,16.8] 15.3 [13.8,16.8]
2017 13.1 [12.7,13.6] 18.7 [18.3,19.1] 24.2 [23.9,24.6]
2018 34.1 [33.9,34.3] 49.7 [49.5,49.9] 65.3 [65.1,65.5]
2019 51.0 [50.3,51.8] 51.0 [50.3,51.8] 51.0 [50.3.51.8]
2020 47.5 [47.3,47.7] 67.3 [67.1,67.4] 87.0 [86.8,87.1]
2021 74.2 [74.0,74.4] 100.7 [100.5,100.9] 127.2 [127.0,127.3]
2022 78.4 [78.3,78.6] 102.1 [101.9,102.2] 125.7 [125,6.125.9]
2023 87.4 [86.9,87.9] 87.4 [86.9,87.9] 87.4 [86.9,87.9]
2024 85.4 [84.9,85.9] 85.4 [84.9,85.9] 85.4 [84.9,85.9]
2025 117.6 [117.2,118.1] 117.6 [117.2,118.1] 117.6 [117.2,118.1]
2026 98.6 [98.1,99.1] 98.6 [98.1,99.1] 98.6 [98.1,99.1]
2027 102.8 [102.7,103.0] 133.0 [132.9,133.1] 163.2 [163.1,163.3]
2028 101.9 [101.8,102.0] 133.4 [133.2,133.5] 164.8 [164.7,164.9]
2029 102.6 [102.5,102.7] 143.4 [143.3,143.6] 184.3 [184.2,184.4]
2030 139.3 [138.9,139.7] 139.3 [138.9,139.7] 139.3 [138.9,139.7]
2031 110.2 [110.1,110.4] 148.4 [148.2,148.5] 186.5 [186.4,186.6]
2032 146.1 [145.7,146.5] 146.1 [145.7,146.5] 146.1 [145.7,146.5]
2033 112.8 [112.7,112.9] 153.0 [152.9,153.1] 193.2 [193.1,193.3]
2034 150.0 [149.6,150.4] 150.0 [149.6,150.4] 150.0 [149.6,150.4]
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Tables 3.6 and 3.7 show the increase of the number of surveillance colonoscopies
through time for an increase in positivity of 1% and conditioned on 3 different levels
of participation. This tables are almost equal because they just change in the years
which model has a non-negative value in the coefficient of the participation and the
positivity to the square.
As we can see this increase is, in general, higher through time and in addition is
higher as long as the value of the participation increase due to the positive value
of the interaction between positivity and participation.
Table 3.7. Increase in the number of surveillance colonoscopies by in-
creasing positivity
Increase of Increase of Increase of
surveillance surveillance surveillance
colonoscopies colonoscopies colonoscopies
YEAR for an increase for an increase for an increase
from 5% to 6% from 5% to 6% from 5% to 6%
in positivity in positivity in positivity
with a participation with a participation with a participation
of 40% of 50% of 60%
2016 15.3 [13.8,16.8] 15.3 [13.8,16.8] 15.3 [13.8,16.8]
2017 13.1 [12.7,13.6] 18.7 [18.3,19.1] 24.2 [23.9,24.6]
2018 34.1 [33.9,34.3] 49.7 [49.5,49.9] 65.3 [65.1,65.5]
2019 62.4 [61.8,63.0] 62.4 [61.8,63.0] 62.4 [61.8,63.0]
2020 47.5 [47.3,47.7] 67.3 [67.1,67.4] 87.0 [86.8,87.1]
2021 74.2 [74.0,74.4] 100.7 [100.5,100.9] 127.2 [127.0,127.3]
2022 78.4 [78.3,78.6] 102.1 [101.9,102.2] 125.7 [125.6,125.9]
2023 87.4 [86.9,87.9] 87.4 [86.9,87.9] 87.4 [86.9,87.9]
2024 104.4 [103.9,104.9] 104.4 [103.9,104.8] 104.4 [103.9,104.8]
2025 117.6 [117.2,118.1] 117.6 [117.2,118.1] 117.6 [117.2,118.1]
2026 120.5 [120.0,120.9] 120.5 [120.0,120.9] 120.5 [120.0,120.9]
2027 102.8 [102.7,103.0] 133.0 [132.9,133.1] 163.2 [163.1,163.3]
2028 101.9 [101.8,102.0] 133.4 [133.2,133.5] 164.8 [164.7,164.9]
2029 102.6 [102.5,102.7] 143.4 [143.3,143.6] 184.3 [184.2,184.4]
2030 139.3 [138.9,139.7] 139.3 [138.9,139.7] 139.3 [138.9,139.7]
2031 110.2 [110.1,110.4] 148.4 [148.2,148.5] 186.5 [186.4,186.6]
2032 146.1 [145.7,146.5] 146.1 [145.7,146.5] 146.1 [145.7,146.5]
2033 112.8 [112.7,112.9] 153.0 [152.9,153.1] 193.2 [193.1,193.3]
2034 150.0 [149.6,150.4] 150.0 [149.6,150.4] 150.0 [149.6,150.4]
In the same way we can estimate of the increase of the number of surveillance
colonoscopies when the participation increases from x to x+10 % with a positivity
PO. In this case it will be by 10% and not by 1% because a 1% of PA is not
relevant for the magnitude of the variable, as we seen in the models for the number
of colonoscopies after a positive FIT.
 β0 + (x+ 10) · β1 +PO · β2 +AD · β3 + (x+ 10)2 · β11 +

PO2 · β22+
+(x+ 10) · PO · β12
− β0 − x · β1 −PO · β2 −AD · β3 − x2 · β11 −

PO2 · β22−
−x · PO · β12 =
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= 10 · β1 + (20x+ 100) · β11 + 10 · PO · β12
which variance, calculated as previously, is:
V ar(10 · β1 + (20x+ 100) · β11 + 10 · PO · β12) =
= 100 · V ar(β1) + (20x+ 100)2 · V ar(β11) + 100 · PO2 · V ar(β12)+
+100 · (20x+ 100)2 · Cov(β1, β11) + 10, 000 · PO2 · Cov(β1, β12)+
+(20x+ 100)2 · 100 · PO2 · Cov(β11, β12)
and this time, the confidence intervals are:
IC95% = 10 · β1 + (20x+ 100) · β11 + 10 · PO · β12±
±1.96 · (V ar(10 · β1 + (20x+ 100) · β11 + 10 · PO · β12))/n) 12
Table 3.8. Increase in the number of surveillance colonoscopies increas-
ing participation
Increase of Increase of Increase of
surveillance surveillance surveillance
colonoscopies colonoscopies colonoscopies
YEAR for an increase for an increase for an increase
from 40% to 50% from 40% to 50% from 40% to 50%
in participation in participation in participation
with a positivity with a positivity with a positivity
of 4% of 5% of 6%
2016 41.0 [39.6,42.4] 41.0 [39.6,42.4] 41.0 [39.6,42.4]
2017 24.9 [24.5,25.3] 30.4 [30.0,30.8] 36.0 [35.6,36.3]
2018 66.3 [66.1,66.5] 81.9 [81.7,82.1] 97.5 [97.3,97.7]
2019 84.9 [93.4,95.3] 84.9 [93.4,95.3] 84.9 [93.4,95.3]
2020 90.1 [89.9,90.3] 109.8 [109.6,110] 129.5 [129.4,129.7]
2021 126.9 [126.7,127.1] 153.3 [153.1,153.5] 179.8 [179.6,180.0]
2022 135.6 [135.5,135.8] 159.3 [159.1,159.4] 182.9 [182.8,183.0]
2023 157.4 [156.7,158.1] 157.4 [156.7,158.1] 157.4 [156.7,158.1]
2024 137.8 [152.4,153.8] 137.8 [152.4,153.8] 137.8 [152.4,153.8]
2025 187.3 [186.7,188.0] 187.3 [186.7,188.0] 187.3 [186.7,188.0]
2026 140.6 [155.5,156.9] 140.6 [155.5,156.9] 140.6 [155.5,156.9]
2027 168.6 [168.4,168.7] 198.7 [198.6,198.9] 228.9 [228.8,229.1]
2028 173.0 [172.9,173.1] 204.4 [204.3,204.6] 235.9 [235.8,236.0]
2029 167.5 [167.4,167.6] 208.3 [208.2,208.5] 249.2 [249.1,249.3]
2030 207.5 [206.9,208.2] 207.5 [206.9,208.2] 207.5 [206.9,208.2]
2031 183.2 [183.0,183.3] 221.3 [221.2,221.5] 259.5 [259.4,259.6]
2032 216.5 [215.9,217.1] 216.5 [215.9,217.1] 216.5 [215.9,217.1]
2033 184.0 [183.8,184.1] 224.2 [224.1,224.3] 264.4 [264.3,264.5]
2034 172.9 [172.4,173.4] 172.9 [172.4,173.4] 172.9 [172.4,173.5]
In the tables 3.8 and 3.9 it is shown the increase in the number of surveillance
colonoscopies when participation is increased in a 10%, through time and for a
population of 100,000 inhabitants conditioned to 3 different values of positivity and
for an adherence of 52.06% (The mean of the simulations).
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Table 3.9. Increase in the number of surveillance colonoscopies increas-
ing participation
Increase of Increase of Increase of
surveillance surveillance surveillance
colonoscopies colonoscopies colonoscopies
YEAR for an increase for an increase for an increase
from 50% to 60% from 50% to 60% from 50% to 60%
in participation in participation in participation
with a positivity with a positivity with a positivity
of 4% of 5% of 6%
2016 41 [39.6,42.4] 41 [39.6,42.4] 41.0 [39.6,42.4]
2017 24.9 [24.5,25.3] 30.4 [30.0,30.8] 36.0 [35.6,36.3]
2018 66.3 [66.1,66.5] 81.9 [81.7,82.1] 97.5 [97.3,97.7]
2019 105.8 [114.5,116.1] 115.3 [114.5,116.1] 115.3 [114.5,116.1]
2020 90.1 [89.9,90.3] 109.8 [109.6,110.0] 129.5 [129.4,129.7]
2021 126.9 [126.7,127.1] 153.3 [153.1,153.5] 179.8 [179.6,180.0]
2022 135.6 [135.5,135.8] 159.3 [159.1,159.4] 182.9 [182.8,183.0]
2023 157.4 [156.7,158.1] 157.4 [156.7,158.1] 157.4 [156.7,158.1]
2024 171.8 [186.5,187.7] 187.1 [186.5,187.7] 187.1 [186.5,187.7]
2025 187.3 [186.7,188.0] 187.3 [186.7,188.0] 187.3 [186.7,188.0]
2026 175.3 [190.4,191.5] 190.9 [190.4,191.5] 190.9 [190.4,191.5]
2027 168.6 [168.4,168.7] 198.7 [198.6,198.9] 228.9 [228.8,229.1]
2028 173.0 [172.9,173.1] 204.4 [204.3,204.6] 235.9 [235.8,236.0]
2029 167.5 [167.4,167.6] 208.3 [208.2,208.5] 249.2 [249.1,249.3]
2030 207.5 [206.9,208.2] 207.5 [206.9,208.2] 207.5 [206.9,208.2]
2031 183.2 [183.0,183.3] 221.3 [221.2,221.5] 259.5 [259.4,259.6]
2032 216.5 [215.9,217.1] 216.5 [215.9,217.1] 216.5 [215.9,217.1]
2033 184.0 [183.8,184.1] 224.2 [224.1,224.3] 264.4 [264.3,264.5]
2034 172.9 [172.4,173.4] 172.9 [172.4,173.4] 172.9 [172.4,173.5]
In this case we can see that like the previous one that, except in some cases, the
increase of number of colonoscopies is higher through time, and this increase is
always equal or higher when positivity rises.
3.2.4. Validation of the linear models.
As said before, to validate a linear model it has to pass 4 tests to check the 4
assumptions. Despite all have been validated, as there are 40 models, in this work
we will show just the validation of three models of each type, chosen randomly.
> sample(1:20,3,replace=F)
[1] 16 4 12
So, the years randomly choose have been the 2018, 2026 and 2030, that corresponds
to the models:
Modelc4:
NScreening = −61.35 + PA · 1.49 + PO · 13.73 + PA · PO · 4.09
Modelc12:
NScreening = 8.07 + PA · 1.04 + PO · 9.15 + PA · PO · 4.64
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Modelc16:
NScreening = −22.05 + PA · 1.52 + PO · 16 + PA · PO · 4.82
Models4:
NSurvei = 195.9 + PA · 0.39− PO · 28.33−AD ·+0.01 + PA · PO · 1.56
Models12:
NSurvei = 99.22 +AD · 3.27 + PA2 · 0.17 + PO2 · 10.95
Models16:
NSurvei = −859.87 + PA · 20.75 + PO · 139.27 +AD · 4.63
1.- Linearity: We will use Ramsay’s reset test to check the linearity of the model,
























RESET = 10.304, df1 = 2, df2 = 1629, p-value = 3.575e-05
As p-value is lower than 0.05 there is no evidence to reject the hypothesis of
linearity.
2.- Normality: As we can not use the Shapiro-Wilk test, because it is indicated
to populations with n < 50, we will use the Lilliefors (Kolmogorov-Smirnov)
test with the R function “lillie.test” of the package nortest.
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> lillie.test(modelc4$residuals)
Lilliefors (Kolmogorov-Smirnov) normality test
data: modelc4$residuals
D = 0.017033, p-value = 0.2988
> lillie.test(modelc12$residuals)
Lilliefors (Kolmogorov-Smirnov) normality test
data: modelc12$residuals
D = 0.018326, p-value = 0.2024
> lillie.test(modelc16$residuals)
Lilliefors (Kolmogorov-Smirnov) normality test
data: modelc16$residuals
D = 0.013059, p-value = 0.7158
> lillie.test(models4$residuals)
Lilliefors (Kolmogorov-Smirnov) normality test
data: models4$residuals
D = 0.024263, p-value = 0.2511
> lillie.test(models12$residuals)
Lilliefors (Kolmogorov-Smirnov) normality test
data: models12$residuals
D = 0.022282, p-value = 0.05616
> lillie.test(models16$residuals)
Lilliefors (Kolmogorov-Smirnov) normality test
data: models16$residuals
D = 0.017478, p-value = 0.2626
We accept the null hypothesis of normality of residuals in all cases.
3.- Homocedasticity.: We will use the Harrison McCabe test, using the R func-












HMC = 0.50406, p-value = 0.628
> hmctest(models4)
Harrison-McCabe test
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data: models4








HMC = 0.48304, p-value = 0.172
We accept the null hypothesis of homocedasticity in all cases.
























X-squared = 2.0234, df = 1, p-value = 0.1549
As the p-value is higher than 0.05 under the level of significance of 95% we
accept the null hypothesis of independence
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In summary, with the linear models we have checked how participation, adherence
and positivity affect to the number of colonoscopies. It has been proved that posi-
tivity is the most sensitive variable, and its effect is ten times higher than the effect
of participation. An increase in adherence also provokes an increase in the number
of colonoscopies, and this increase will ne higher as long as time passes.
Using this models, we can predict the number of both colonoscopies after positive
FIT and those of surveillance for each endoscopic unit, applying to this models the
specific territorial levels of adherence, positivity and participation.
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3.3. Application
This sensitivity analysis has two practical applications. It allows to asses how the
variability associated with the estimation of the adherence, positivity and partici-
pation affects the results, but also to predict with a value of this three variables the
number of both after a positive FIT and surveillance colonoscopies that is going to
do an endoscopic unit a determined year, just using the respective model.
To show this results in a clean and easy-to-handle way, an application was created
using the R software Shiny. This application shows the barplot of the number of
colonoscopies per year of the selected type and endoscopic unit. Additional sidebar
are included to change participation, positivity and adherence. We can see the
interface in figures 3.3 and 3.4. The R code of the entire application its placed
in the appendix with all the R code of this dissertation. The app is uploaded at
“jlae.shinyapps.io/CRCpredictor ” and it can be used using the username “CRC”
and the password “1234 ” .
Fig. 3.3. Interface of the shiny app, colonoscopies slider
In addition to this information we have 2 buttons, the first one “Download XLS”
allows to download an excel file with the number of colonoscopies both after a pos-
itive FIT and surveillance, and the total, for the selected population, participation,
adherence and positivity. We can see this button on figure 3.5. The second button
allows you to download the plot in pdf. We can see it on figure 3.6.
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Fig. 3.4. Interface of the shiny app, population slider
Briefly this is a friendly-user way to show the results of the sensitivity analysis
and is useful for decision-makers to predict the future number of colonoscopies by
selecting the variables and the population of interest.
Fig. 3.5. The “Download XLS button”
46 3. SENSITIVITY ANALYSIS
Fig. 3.6. The “Download plot button”
With this application, each manager can select an endoscopic unit, and, introducing
the different values of participation, adherence and positivity that corresponds to
this territory, predict the resources this endoscopic unit will need in the future
twenty years to meet the predicted needs of colonoscopies.
Chapter 4
Future refinements of the model
Statisticians, like artists, have the bad habit
of falling in love with their models
- George E.P. Box
The aim of this chapter is to explain how this model will be improved in the future
to provide more refined territorial predictions.
The specific territorial predictions shown in the previous chapter were calculated
by re-scaling the results of the model (for a population of 100,000 inhabitants) to
the size of each population.
The main restriction of this model is that it considers that the populations have
the same age and sex structure and differ by population number only. Age and sex
structure is similar among Healthcare Regions (RS), but at the level of endoscopic
units relevant differences appear. As inputs depend both on age and sex, and
outputs will be affected by difference in the population.
Two solutions were considered, to create a model for each endoscopic unit, which
was discarded by the great time consumption of executing the model 38 times, or
modifying inputs to represent equally all combinations of age and gender and collect
outputs to re-scale them according to the specific structure of each population.
Thus, the model will give the following information:
- 38 Factors representing the number of colonoscopies after positive FIT per year
for each “n” habitants, by sex (male or female) and age (yearly).
- 38 Factors representing the number of surveillance colonoscopies per year for each
“n ” inhabitants, by sex (male or female) and age (yearly).
- 40 factors representing the number of colonoscopies after positive FIT per year for
each “n” habitants, each one for a sex (male or female) and for those individuals
who turn 50 years in a year between 2016 and 2035.
- 40 factors representing the number of surveillance colonoscopies for each “n”
habitants per year, each one for a sex (male or female) and for those individuals
who turn 50 years in a year between 2016 and 2035.
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That is a total of 156 factors that make up two matrix (we call those matrix C and
S) with 20 rows and 78 columns each as follows:
C =

CCM,2016 CCF,2016 CCYM,2016 CCYF,2016










CSM,2016 CSF,2016 CSYM,2016 CSYF,2016





CSM,2035 CSF,2035 CSYM,2035 CSYF,2035

where:
CCM,y = {CCM,y,i}i∈{51,··· ,69} a vector where each CCM,y,i represents the
number of colonoscopies after positive FIT made to males of age “i” in the
year “y” per “n” habitants (with a previously fixed “n”).
CCF,y = {CCF,y,i}i∈{51,··· ,69} a vector where each CCF,y,i represents the num-
ber of colonoscopies after positive FIT made to females of age “i” in the year
“y” per “n” habitants (with a previously fixed “n”).
CCYM,y = {CCYM,y,j}j∈{2016,··· ,2035} a vector where each CCYM,y,j represents
the number of colonoscopies after positive FIT made in the year “y” to males
that turned 50 years old the year “j” per “n” inhabitants (with a previously
fixed “n”).
CCYF,y = {CCYF,y,j}j∈{2016,··· ,2035} a vector where each CCYF,y,j represents
the number of colonoscopies after positive FIT made in the year “y” to females
that turned 50 years old the year “j” per “n” habitants (with a previously
fixed “n”).
CSM,y = {CSM,y,i}i∈{51,··· ,69} a vector where each CSM,y,i represents the num-
ber of surveillance colonoscopies made to males of age “i” in the year “y” per
“n” habitants (with a previously fixed “n”) .
CSF,y = {CSF,y,i}i∈{51,··· ,69} a vector where each CSF,y,i represents the num-
ber of surveillance colonoscopies made to females of age “i” in the year “y”
per “n” habitants (with a previously fixed “n”).
CSYM,y = {CSYM,y,j}j∈{2016,··· ,2035} a vector where each CSYM,y,j represents
the number of surveillance colonoscopies made in the year “y” to males that
turned 50 years old the year “j” per “n” inhabitants (with a previously fixed
“n”).
CSYF,y = {CSYF,y,j}j∈{2016,··· ,2035} a vector where each CSYF,y,j represents
the number of surveillance colonoscopies in the year “y” made to females that
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had turned 50 years old the year “j” per “n” habitants (with a previously
fixed “n”).
This new model is rescheduled to begin in 2016 instead of 2015 as the one explained
on chapter 2.
The Director Plan of Oncology of Catalonia provided the number of inhabitants
aged 50 to 69 years assigned to every endoscopic unit, as well as the number of
inhabitants who will turn 50 in the next two years, all calculated based on data
from the Central Registry of Insured Persons (RCA). Hence the population of
each endoscopic unit who turns 50 in 2016, 2017 and 2018 was obtained. For
the remaining years until 2035 INEbase data was used.
Since this time the prediction will be made for each endoscopic unit, instead of
using the prediction of Catalonia the prediction of each province was used. So for
each endoscopic unit we assume that the number of inhabitants aged 50 years old
from 2019-2029 will follow the same patter as the one of the province where the
endoscopic unit is located. Between 2029 and 2035 we use data at the Spanish level
as INEbase does not provide estimations beyond 2029 neither by province nor by
Autonomous Region.
Fig. 4.1. Males who will turn 50 per year in a population of 100,000
In figure 4.1 it is shown the number of individuals that turn 50 for each province
per 100,000 men and in figure 4.2 per 100,000 women.
Both in males and females plots the estimated number of 50 year old inhabitants
grow until 2027 in all regions and decrease since then. It has to be remembered that
these estimates are new and this decrease was not observed in earlier predictions
used in the previous model, as we can see comparing the new barplot of population
(figure 4.3) with the one used before (figure 2.4). This makes even more necessary
to readjust the model results.
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Fig. 4.2. Females who will turn 50 per year in a population of 100,000
With these new model that we created restructuring the previous one we can pre-
dict the number of both after positive FIT and surveillance colonoscopies for each
endoscopic unit taking in to account how the population is distributed in terms of
age or sex.
Fig. 4.3. New prediction of 50 year old population of Catalonia
For each endoscopic unit we can build the column vector V of length 78:
V = (NM51, · · · , NM69, NF51, · · · , NF69, NMY2016, · · · , NMY2035, NFY2016, · · · , NFY2035)t
with:
NMi: Number of males of age “i”.
NFi: Number of females of age “i”.
NMYj : Number of males who turn 50 on year “j”.
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NFYj : Number of males who turn 50 on year “j”.
So finally we will compute the vectors CC and CS where:
(CC)t = C · V
(CS)t = S · V
the fact that C, S ∈ M20,78 and V ∈ M78,1 implies that (CC)t ∈ M20,1 and
(CS)t ∈M20,1 and so CC and CS will be two row vectors of length 20; CC ∈M1,20,
CC = (CC1, · · · , CC20) and CS ∈M1,20, CS = (CS1, · · · , CS20) where each CCy
will be the number of colonoscopies after positive FIT on year “y” and each CSy
will be the number of surveillance colonoscopies on year “y”.
As an example, we will show preliminary results for one endoscopic unit.
In the table 4.1 we can see the future prediction of colonoscopies for the endoscopic
unit of “Hospital del Mar” predicted with this new model. This area has a target
population of 69,147 inhabitants.
As it is shown this endoscopic unit will have to do 14,371 colonoscopies over the 20
year-horizon. From the differences between the number of colonoscopies that are
predicted for men and women, we can see the importance of including an accurate
gender distribution.
Table 4.1. Results on number of colonoscopies of the new model in
“Hospital del Mar”
After After Total
positive positive Surveillance Surveillance after Total
YEAR FIT of FIT of of of positive Surveillance Total
Men women Men women FIT
2016 177.8 274.8 0.0 0.0 452.5 0.0 452.5
2017 176.0 270.7 26.7 40.2 446.6 67.0 513.6
2018 188.0 209.2 27.2 41.6 397.1 68.8 466.0
2019 183.0 209.6 73.1 97.0 392.6 170.1 562.7
2020 197.8 208.0 94.2 130.1 405.9 224.3 630.1
2021 203.6 215.9 102.1 118.6 419.5 220.8 640.3
2022 215.4 217.7 137.8 160.9 433.1 298.7 731.8
2023 217.3 215.0 145.0 167.0 432.3 312.0 744.3
2024 223.2 219.6 150.2 158.3 442.8 308.5 751.3
2025 233.4 221.5 176.2 186.1 454.9 362.4 817.3
2026 237.5 220.4 184.6 187.1 457.9 371.7 829.6
2027 230.3 221.2 186.3 184.0 451.5 370.3 821.8
2028 233.8 216.9 192.7 189.4 450.7 382.1 832.8
2029 230.8 216.2 200.3 184.1 447.0 384.3 831.4
2030 228.8 212.2 194.1 183.8 441.1 377.9 819.0
2031 231.8 213.3 200.7 187.6 445.0 388.4 833.4
2032 219.6 206.4 207.9 185.5 426.0 393.4 819.4
2033 215.7 198.5 196.1 182.5 414.1 378.5 792.7
2034 200.1 175.5 194.6 173.6 375.6 368.2 743.8
2035 196.2 178.0 196.7 166.3 374.2 363.1 737.3
TOTAL 14361
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It is also important to see how the impact of the new predictions on population
ageing, as a decrease in, both after positive FIT and surveillance from the year 2031
is observed, coinciding with the decrease in the population of 50-year olds predicted
by INEbase data.
In the figure 4.4 it is shown a bar plot with this results.
Fig. 4.4. Average number of colonoscopies predicted for the “Hospital
del Mar”
The next step will be to rebuild the sensitivity analysis to estimate new models to
predict the number of colonoscopies to each endoscopic unit varying the positivity,




Contrariwise, if it was so, it might be;
and if it were so, it would be;
but as it isn’t, it ain’t.
That’s logic.
- Lewis Carroll 1
Despite colorectal cancer has a relatively low mortality rate if detected early, is
still the second leading cause of cancer death in Spain and, more specifically, in
Catalonia. The fact that CRC screening is currently being extended in Catalonia
makes the results of the present dissertation relevant for planning purposes.
As previously was stated, this expansion of the screening program to the whole
territory of Catalonia arises the need of, by statistical means, estimate how the
demand of colonoscopies will be affected by the needs generated by the screening
program. Our study presents a discrete event simulation model of a population-
based colorectal screening program following the European Guidelines that provides
a valuable source of information for health care services planning.
In short, we managed to achieve the main objective of this project, as we have
defined a mathematical model capable of analysing through discrete event simu-
lation the number of colonoscopies that each endoscopic unit must provide to the
early detection screening program of colorectal cancer in Catalonia, due to the early
detection Colorectal Cancer Screening Program of Catalonia.
The conclusions in terms of results we have drawn is that for the population of all
Catalonia the total number of colonoscopies increase from 21,286 in the first year,
passing on 39.060 passed 10 years, to 45,319 after 20 years, making a total of almost
730,000 colonoscopies during these 20 years according to the model predictions. Of
these 730,000 colonoscopies the 60% will be colonoscopies after a positive FIT, and
40% will be those for the surveillance of the detected pre-malignant lesions.
This model also predicted a strong increase in participation from 2017 (up to 10%)
and a clear decrease in positivity (in a bit more than 1.5%) also from 2017 due to
the increase of successive screening.
1See Carrol L. (1872)
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Besides, using linear models a sensitivity analysis has been performed, which al-
lowed us to see the impact on the number of colonoscopies of the uncertainty associ-
ated with the estimation of the adherence, positivity and participation parameters.
Moreover, it allowed predicting the number of colonoscopies for some value of these
three parameters, and translating these findings into a simple web application.
Despite trying mixed-effects models, a full sensitivity analysis was done by creating
general linear models by year and we could conclude that an increase of adherence,
participation and positivity rates increase the number of colonoscopies, but with
different magnitude.
Adherence affects to the number of surveillance colonoscopies only, and it is the
variable with the lowest effect in magnitude. An increase of a 10% in this variable
make an increase of between 0 colonoscopies in the short-term to over 50 in the long-
term. In general this increment does not depend on participation and positivity
rates.
The participation also increment more the number of colonoscopies in the long-
term than in the short-term. This increase is also higher as higher is the positivity
due to the interaction between this variables. In average, an increase of a 10% in
the participation will increase the number of colonoscopies after positive FIT in
around 200 in the first year, 280 after ten years (in 2024) and in 320 at the end of
the time horizon of the simulation. On the other hand, in average, an increase of a
10% in the participation will increase the number of surveillance colonoscopies on
less than 50 in the second and third year (the first year the number of surveillance
colonoscopies is always null because surveillance has not started yet), in 137 in 2024
and in more than 170 in last year.
Finally, the FIT positivity is far the most sensitive variable. Changing a 1% of this
variable is similar on changing a 10% on participation. This increment is affected
also by time and participation. In average, increasing a 1% the positivity will lead
to an increase of 170 colonoscopies after a positive FIT in first year, of 233 on 2024
and of 264 on 2034. In terms of surveillance colonoscopies this increase will be of
less than 20 both in years 2016 and 2017, of 60 on 2024, and around 160 in 2034.
All this previous data is referred to the results of this model, so this increments
will be always per 100,000 inhabitants of the population.
In order to deliver these results for every endoscopic unit in a friendly user way, an
application was created using R software to present customized data for each unit.
This application can be useful for planning the necessary resources in a 20-year
horizon and will be presented to the Technical Screening Office of Catalonia.
One of the limitations of this study is that the simulation of the tests results are
based on empirical distributions according to the results obtained from a program
rather than applying sensitivity and specificity of tests according to the natural
history stage of the disease. Modelling the natural history of the disease was out
of the scope of this study. Another limitation is that surveillance colonoscopies of
cancers detected under the screening program were not taken into account, as they
depend on several individual factors subject to clinical decision.
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Finally, the foresight of the population by province from 2029 on was not available
and we had to adapt the Spanish tendency to all provinces and units, knowing that
the differences in age structure are relevant.
One key strength of this work is that we used data from a CRC screening program
covering around 200.000 inhabitants, compliant with the European Guidelines for
Quality Assurance. Age and sex-specific parameters were estimated from the areas
corresponding to the CRC screening program of Barcelona between 2009 and 2015.
Moreover, the present dissertation develops a sensitivity analysis methodology using
regression models to assess the effect of crucial parameters on the outputs of the
model and through time and achieves, through the development of an application,
a friendly-user and interactive way to present results to decision-makers. However,
future work, as introduced in this dissertation, is needed to improve the accuracy of
predictions by endoscopic unit taking into account future population predictions.
In conclusion, this simulation model and its analysis have shown to be powerful
tools for health services planning and to inform decision-making. Beyond the mod-
elling/technical matters, this piece of research should facilitate reflections on the
capacity of the health system to meet the demand of colonoscopies induced by

























R CODE: Sensitivity analysis, mixed
effects models
### ~MIXED EFFECTS~ ###











boxplot(ranef(lme.1)[,1],main="Random effects on the intercept"
,ylim=c(-250,250))
abline(h=1)



















R CODE: Sensitivity analysis, lin-
ear models
























































































































































































































R CODE: Shiny app
D.1. Server: Beginning and charging interface
### ~APP SERVER~ ###





withProgress(message = ’Loading’, value = 0, {
n <- 100
for (i in 1:n) {

















if (input$pob==" Barcelona - Sud l’Hospitalet LL") {factor<-60996}
if (input$pob==" Barcelona - Sud Alt Penede`s") {factor<-21974}
if (input$pob==" Barcelona - Ciutat Esquerra i Litoral") {factor<-198911}
if (input$pob==" Lleida tot excepte LLeida") {factor<-84210}
if (input$pob==" Terres Ebre Baix Ebre") {factor<-19103}
if (input$pob==" Girona Baix Emporda`, Garrotxa, Ripolle`s") {factor<-50328}
if (input$pob==" Catalunya Central Osona") {factor<-37254}
if (input$pob==" Camp de Tarragona Alt Camp-Conca") {factor<-14554 }
if (input$pob==" Alt Pirineu i Aran Cerdanya, Pallars, Urgell") {factor<-13091}
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if (input$pob==" Barcelona Nord V Occ est") {factor<- 100375}
if (input$pob==" Barcelona Nord el Prat") {factor<-15996}
if (input$pob==" Barcelona - Sud Maresem Central (o BN Baix maresme, doble)") {factor<-62915}
if (input$pob==" Catalunya Central Solsone`s, Bages, Bergueda`") {factor<-60238}
if (input$pob==" Alt Pirineu i Aran La Cerdanya") {factor<-3616}
if (input$pob==" Terres Ebre Montsia` + Altebrat (resta TE)") {factor<-24908}
if (input$pob==" Barcelona - Barcelona Dreta") {factor<-108564}
if (input$pob==" Girona Alt Emporda`") {factor<-31643}
if (input$pob==" Girona Girone`s") {factor<-50112}
if (input$pob==" Camp Tarragona Tarragone`s-Baix Penede`s") {factor<-75480}
if (input$pob==" Barcelona - Sud Alt Penede`s Garraf") {factor<-36077}
if (input$pob==" Barcelona - Sud Baix Llobregat Centre-Litoral i LH.LL.") {factor<-143167}
if (input$pob==" Barcelona - Sud Baix Llobregat Nord") {factor<-32985}
if (input$pob==" Barcelona Nord Valle`s Occidental Oest") {factor<-96611}
if (input$pob==" Barcelona Nord Valle`s Oriental") {factor<-101513}
if (input$pob==" Barcelona ciutat Nord") {factor<-92487}
if (input$pob==" Barcelona Nord B Nord i Baix Maresme") {factor<-104105}
if (input$pob==" Camp de Tarragona Baix Camp-Priorat") {factor<-46625}
if (input$pob==" Catalunya Central Anoia") {factor<-25922}
if (input$pob==" Girona Alt Maresme") {factor<-26738}
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pred2<-(pred2*factor)/100000
for (i in 1:20){
if(pred1[i]<0){pred1[i]<-0}
}






























D.3. Server: Download XLS button
output$downloadData <- downloadHandler(
filename = function() {
paste("prediction_", input$par, "_",input$pos, "_", input$adh, ’.xls’, sep=’’)
},
content = function(file) {
if (input$pob==" Barcelona - Sud l’Hospitalet LL") {factor<-60996}
if (input$pob==" Barcelona - Sud Alt Penede`s") {factor<-21974}
if (input$pob==" Barcelona - Ciutat Esquerra i Litoral") {factor<-198911}
if (input$pob==" Lleida tot excepte LLeida") {factor<-84210}
if (input$pob==" Terres Ebre Baix Ebre") {factor<-19103}
if (input$pob==" Girona Baix Emporda`, Garrotxa, Ripolle`s") {factor<-50328}
if (input$pob==" Catalunya Central Osona") {factor<-37254}
if (input$pob==" Camp de Tarragona Alt Camp-Conca") {factor<-14554 }
if (input$pob==" Alt Pirineu i Aran Cerdanya, Pallars, Urgell") {factor<-13091}
if (input$pob==" Barcelona Nord V Occ est") {factor<- 100375}
if (input$pob==" Barcelona Nord el Prat") {factor<-15996}
if (input$pob==" Barcelona - Sud Maresem Central (o BN Baix maresme, doble)") {factor<-62915}
if (input$pob==" Catalunya Central Solsone`s, Bages, Bergueda`") {factor<-60238}
if (input$pob==" Alt Pirineu i Aran La Cerdanya") {factor<-3616}
if (input$pob==" Terres Ebre Montsia` + Altebrat (resta TE)") {factor<-24908}
if (input$pob==" Barcelona - Barcelona Dreta") {factor<-108564}
if (input$pob==" Girona Alt Emporda`") {factor<-31643}
if (input$pob==" Girona Girone`s") {factor<-50112}
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if (input$pob==" Camp Tarragona Tarragone`s-Baix Penede`s") {factor<-75480}
if (input$pob==" Barcelona - Sud Alt Penede`s Garraf") {factor<-36077}
if (input$pob==" Barcelona - Sud Baix Llobregat Centre-Litoral i LH.LL.") {factor<-143167}
if (input$pob==" Barcelona - Sud Baix Llobregat Nord") {factor<-32985}
if (input$pob==" Barcelona Nord Valle`s Occidental Oest") {factor<-96611}
if (input$pob==" Barcelona Nord Valle`s Oriental") {factor<-101513}
if (input$pob==" Barcelona ciutat Nord") {factor<-92487}
if (input$pob==" Barcelona Nord B Nord i Baix Maresme") {factor<-104105}
if (input$pob==" Camp de Tarragona Baix Camp-Priorat") {factor<-46625}
if (input$pob==" Catalunya Central Anoia") {factor<-25922}
if (input$pob==" Girona Alt Maresme") {factor<-26738}
















































for (i in 1:20){
if(pred1[i]<0){pred1[i]<-0}
}
for (i in 1:20){
if(pred2[i]<0){pred2[i]<-0}
}










WriteXLS("d",ExcelFileName = file, SheetNames = "Prediction")
})
D.4. Server: Download plot button
output$downloadpdf <- downloadHandler(
filename = function() {
paste("prediction_", input$par, "_",input$pos, "_", input$adh, ’.pdf’, sep=’’)
},
content = function(file) {
if (input$pob==" Barcelona - Sud l’Hospitalet LL") {factor<-60996}
if (input$pob==" Barcelona - Sud Alt Penede`s") {factor<-21974}
if (input$pob==" Barcelona - Ciutat Esquerra i Litoral") {factor<-198911}
if (input$pob==" Lleida tot excepte LLeida") {factor<-84210}
if (input$pob==" Terres Ebre Baix Ebre") {factor<-19103}
if (input$pob==" Girona Baix Emporda`, Garrotxa, Ripolle`s") {factor<-50328}
if (input$pob==" Catalunya Central Osona") {factor<-37254}
if (input$pob==" Camp de Tarragona Alt Camp-Conca") {factor<-14554 }
if (input$pob==" Alt Pirineu i Aran Cerdanya, Pallars, Urgell") {factor<-13091}
if (input$pob==" Barcelona Nord V Occ est") {factor<- 100375}
if (input$pob==" Barcelona Nord el Prat") {factor<-15996}
if (input$pob==" Barcelona - Sud Maresem Central (o BN Baix maresme, doble)") {factor<-62915}
if (input$pob==" Catalunya Central Solsone`s, Bages, Bergueda`") {factor<-60238}
if (input$pob==" Alt Pirineu i Aran La Cerdanya") {factor<-3616}
if (input$pob==" Terres Ebre Montsia` + Altebrat (resta TE)") {factor<-24908}
if (input$pob==" Barcelona - Barcelona Dreta") {factor<-108564}
if (input$pob==" Girona Alt Emporda`") {factor<-31643}
if (input$pob==" Girona Girone`s") {factor<-50112}
if (input$pob==" Camp Tarragona Tarragone`s-Baix Penede`s") {factor<-75480}
if (input$pob==" Barcelona - Sud Alt Penede`s Garraf") {factor<-36077}
if (input$pob==" Barcelona - Sud Baix Llobregat Centre-Litoral i LH.LL.") {factor<-143167}
if (input$pob==" Barcelona - Sud Baix Llobregat Nord") {factor<-32985}
if (input$pob==" Barcelona Nord Valle`s Occidental Oest") {factor<-96611}
if (input$pob==" Barcelona Nord Valle`s Oriental") {factor<-101513}
if (input$pob==" Barcelona ciutat Nord") {factor<-92487}
if (input$pob==" Barcelona Nord B Nord i Baix Maresme") {factor<-104105}
if (input$pob==" Camp de Tarragona Baix Camp-Priorat") {factor<-46625}
if (input$pob==" Catalunya Central Anoia") {factor<-25922}
if (input$pob==" Girona Alt Maresme") {factor<-26738}

















































for (i in 1:20){
if(pred1[i]<0){pred1[i]<-0}
}
























main=paste("Prediction of the number of", input$col, "colonoscopies in", input$pob))
graphics::text(x,bp2[1,]+rep(c(max(pred2)/4,max(pred2)/8),10),













D.5. Server: Introduce Password
USER <<- reactiveValues(Logged = Logged)
observe({
if (USER$Logged == FALSE) {
if (!is.null(input$Login)) {
if (input$Login > 0) {
Username <- isolate(input$userName)
Password <- isolate(input$passwd)
Id.username <- which(my_username == Username)
Id.password <- which(my_password == Password)
if (length(Id.username) > 0 & length(Id.password) > 0) {









if (USER$Logged == TRUE)
{






















label = "Participation:", min = 0.1, max = 100, value = 50, step= 0.1),
sliderInput(inputId = "pos",
label = "Positivity:", min = 2, max = 10, value = 5, step= 0.01),
sliderInput(inputId = "adh",label = "Adherence:", min = 0.1, max = 100, value = 50, step= 0.1)
),
column(6, offset = 1,
selectInput(inputId = "pob",
label = "Population:",
choices = c(" Alt Pirineu i Aran La Cerdanya",
" Alt Pirineu i Aran Cerdanya, Pallars, Urgell",
" Barcelona - Barcelona Dreta",
" Barcelona - Ciutat Esquerra i Litoral",
" Barcelona Nord B Nord i Baix Maresme",
" Barcelona Nord el Prat",
" Barcelona Nord Valle`s Occidental Oest",
" Barcelona Nord Valle`s Oriental"," Barcelona ciutat Nord",
" Barcelona Nord V Occ est",
" Barcelona - Sud Alt Penede`s",
" Barcelona - Sud Alt Penede`s Garraf",
" Barcelona - Sud Baix Llobregat Centre-Litoral i LH.LL.",
" Barcelona - Sud Baix Llobregat Nord",
" Barcelona - Sud l’Hospitalet LL",
" Barcelona - Sud Maresem Central (o BN Baix maresme, doble)",
" Camp de Tarragona Alt Camp-Conca",
" Camp de Tarragona Baix Camp-Priorat",
" Camp Tarragona Tarragone`s-Baix Penede`s",
" Catalunya Central Anoia",
" Catalunya Central Osona",
" Catalunya Central Solsone`s, Bages, Bergueda`",
" Girona Alt Emporda`",
" Girona Alt Maresme",
" Girona Baix Emporda`, Garrotxa, Ripolle`s",
" Girona Girone`s",
" Girona Selva",
" Lleida tot excepte LLeida",
" Terres Ebre Baix Ebre",
" Terres Ebre Montsia` + Altebrat (resta TE)"
),
selected = " Barcelona-Sud l’Hospitalet LL"),
selectInput(inputId = "col",
label = "Type of colonoscopy:",
choices = c("Screening","Surveillance","All"),
selected = "Screening"),
column(5, offset = 1,downloadButton(’downloadData’, ’Download XLS’)),





HTML(’<center><font face="Comic sans MS,arial,verdana" size=2> Created by </font></center><center>
<font face="Comic sans MS,arial,verdana" size=2 color=003399>Javier Louro</font></center><center>’)
),
bsTooltip("par", "Introduce the percentage of participation"),
bsTooltip("pob", "Introduce the population to predict"),
bsTooltip("col", "Introduce the type of colonoscopy"),
bsTooltip("pos", "Introduce the percentage of positivity"),
bsTooltip("adh", "Introduce the percentage of adherence"),






D.7. Server: Read the data and models
read <- function(){
progress <- shiny::Progress$new(session, min=1, max=3)










progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)
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progress <- shiny::Progress$new(session, min=1, max=3)
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progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)







progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)









progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)









progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)








progress <- shiny::Progress$new(session, min=1, max=3)
progress$set(message = "Loading modelsl\cdots",value=4)
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models14 <- readmodels14()
readmodels15 <- function(){
progress <- shiny::Progress$new(session, min=1, max=3)
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progress <- shiny::Progress$new(session, min=1, max=3)
progress$set(message = "Loading modelsl\cdots",value=4)








D.8. UI: Connection to Server








(htmlOutput("page")), plotOutput(’plot’, width = "100px", height = "100px")
))
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